IPGaia and the Icahn School of Medicine at Mount Sinai Announce Comprehensive Collaborative Research and Development Agreement
IPGaia Inc. (“IPG”) and the Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”) have entered into a Comprehensive Collaborative Research and Development Agreement (“this agreement”) dated August 7th, 2024. This agreement establishes a formal framework for the incorporation of promising …
HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms
Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the closing of its license agreements with the …
Icahn School of Medicine at Mount Sinai Licenses Next-Generation Diagnostic Test Epigenetic /AI Platform to GNOMX Corp.
The Icahn School of Medicine at Mount Sinai has agreed to an exclusive license option with GNOMX Corp. (GNOMX) for epigenetic diagnostic and prognostic technology for infectious diseases. This groundbreaking patent-pending technology was developed by collaborating researchers at Icahn Mount Sinai, Princeton …
Promising Results of Next-Generation Intranasal COVID-19 Booster Vaccine: Implications for Infection Prevention and Transmission
The Icahn School of Medicine at Mount Sinai in New York, NY is pleased to announce that CastleVax, Inc. has completed enrollment and a preliminary analysis of a phase 1 trial of its licensed Newcastle disease virus (NDV)-based COVID-19 booster vaccine. The phase …
BeeKeeperAI Raises $12.1 Million Series A to Accelerate AI Development on Privacy Protected Healthcare Data
BeeKeeperAI, Inc., a pioneer in zero-trust, collaboration software for the development and deployment of artificial intelligence (AI), today announced that it has closed $12.1 million in Series A financing. The round was led by Sante Ventures, with participation from the Icahn School …
Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease
Risk scoring by KidneyIntelX resulted in a 4.5-fold increase in new drug prescriptions (for SGLT2 inhibitors) for high risk compared to low risk patients, an observed reduction of HbA1c levels in the highest risk patients, an overall increased use of antihypertensive therapeutics, …
New Blood Test Delivers Highly Accurate Threshold Assay That Enhances Clinical Management for Peanut Allergy
Allergenis’ bead-based epitope assay at center of study from Mount Sinai revealing breakthrough diagnostic for peanut allergy. Allergenis, a predictive data analytics company specializing in the detection and management of life-threatening food allergies, today announced the results of extensive research and development …
Mount Sinai Awarded $11.6 Million Grant to Launch Comprehensive Center for Surgical Innovation and Expand Mount Sinai BioDesign
Work will benefit patients, contribute to job creation and economic growth in New York City. In a move that has the potential to change the future of surgery, advance quality care, and bring economic growth to New York City, Mount Sinai Health …
Mount Sinai Announces the Formation of CastleVax Inc., a Clinical-Stage Infectious Diseases Company Developing Novel Vaccines and Therapeutics, Targeting Pandemic Threats and Diseases of Unmet Medical Need
The Mount Sinai Health System in New York, NY, has launched CastleVax, Inc. (“CastleVax”), a clinical-stage vaccine research and development company. CastleVax is devoted to the commercial development of the Newcastle disease virus (NDV) vaccine platform technology originally developed in the laboratories …
Gromit Therapeutics Announces an Exclusive License Agreement with the Icahn School of Medicine at Mount Sinai
Gromit Therapeutics, a clinical-stage biopharmaceutical company, developing disruptive gene therapies for inflammatory and age related diseases, and the Icahn School of Medicine at Mount Sinai in New York , NY (“Icahn Mount Sinai”) have announced today an exclusive license agreement to the …